Home › Compare › ESIGF vs ABBV
ESIGF yields 1.20% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, ESIGF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of ESIGF + ABBV for your $10,000?
ESI Group SA, together with its subsidiaries, designs, develops, and distributes virtual prototyping software solutions in Europe, the Middle East, Africa, the Asia Pacific, and the Americas. The company offers vibro-acoustics, which allows engineers to perform accurate predictive noise and vibration design assessments early in the design cycle; virtual reality and performance solutions; and virtual seat solutions. It also provides SimulationX, a single platform for modeling, simulating, and analyzing technical systems; SYSWELD, which enables the designers and process planners to virtually manufacture, assemble, and test physically realistic virtual assemblies; SYSTUS, which offers a complete resolution to analysis challenges in mechanics, heat transfer, and electrotechnics; PROSIVIC simulation software; PAM-STAMP that provides sheet metal forming solutions; interior solutions; PAM-COMPOSITES; ACE+ Suite, a CFD and high-fidelity multiphysics simulation software; and ProCAST, which offers casting solutions. In addition, the company offers consulting, technical support and assistance, and training services, as well as operates myESI, a customer portal. It serves aeronautics/aerospace, defense, naval, automotive, energy, ground transportation, heavy machinery, and other industries. The company was founded in 1973 and is headquartered in Rungis, France.
Full ESIGF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.